Head-to-head comparison of magnetic resonance elastography-based liver stiffness, fat fraction, and T1 relaxation time in identifying at-risk NASH
Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc..
BACKGROUND AND AIMS: The presence of at-risk NASH is associated with an increased risk of cirrhosis and complications. Therefore, noninvasive identification of at-risk NASH with an accurate biomarker is a critical need for pharmacologic therapy. We aim to explore the performance of several magnetic resonance (MR)-based imaging parameters in diagnosing at-risk NASH.
APPROACH AND RESULTS: This prospective clinical trial (NCT02565446) includes 104 paired MR examinations and liver biopsies performed in patients with suspected or diagnosed NAFLD. Magnetic resonance elastography-assessed liver stiffness (LS), 6-point Dixon-derived proton density fat fraction (PDFF), and single-point saturation-recovery acquisition-calculated T1 relaxation time were explored. Among all predictors, LS showed the significantly highest accuracy in diagnosing at-risk NASH [AUC LS : 0.89 (0.82, 0.95), AUC PDFF : 0.70 (0.58, 0.81), AUC T1 : 0.72 (0.61, 0.82), z -score test z >1.96 for LS vs any of others]. The optimal cutoff value of LS to identify at-risk NASH patients was 3.3 kPa (sensitivity: 79%, specificity: 82%, negative predictive value: 91%), whereas the optimal cutoff value of T1 was 850 ms (sensitivity: 75%, specificity: 63%, and negative predictive value: 87%). PDFF had the highest performance in diagnosing NASH with any fibrosis stage [AUC PDFF : 0.82 (0.72, 0.91), AUC LS : 0.73 (0.63, 0.84), AUC T1 : 0.72 (0.61, 0.83), |z| <1.96 for all].
CONCLUSION: Magnetic resonance elastography-assessed LS alone outperformed PDFF, and T1 in identifying patients with at-risk NASH for therapeutic trials.
| Errataetall: |
CommentIn: Hepatology. 2023 Oct 1;78(4):1106-1117. - PMID 37021787 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:78 |
|---|---|
| Enthalten in: |
Hepatology (Baltimore, Md.) - 78(2023), 4 vom: 01. Okt., Seite 1200-1208 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Li, Jiahui [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Clinical Trial |
|---|
| Anmerkungen: |
Date Completed 03.10.2023 Date Revised 12.03.2024 published: Print-Electronic ClinicalTrials.gov: NCT02565446 CommentIn: Hepatology. 2023 Oct 1;78(4):1106-1117. - PMID 37021787 Citation Status MEDLINE |
|---|
| doi: |
10.1097/HEP.0000000000000417 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM355843463 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM355843463 | ||
| 003 | DE-627 | ||
| 005 | 20240312233024.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1097/HEP.0000000000000417 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1324.xml |
| 035 | |a (DE-627)NLM355843463 | ||
| 035 | |a (NLM)37080558 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Li, Jiahui |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Head-to-head comparison of magnetic resonance elastography-based liver stiffness, fat fraction, and T1 relaxation time in identifying at-risk NASH |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 03.10.2023 | ||
| 500 | |a Date Revised 12.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a ClinicalTrials.gov: NCT02565446 | ||
| 500 | |a CommentIn: Hepatology. 2023 Oct 1;78(4):1106-1117. - PMID 37021787 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc. | ||
| 520 | |a BACKGROUND AND AIMS: The presence of at-risk NASH is associated with an increased risk of cirrhosis and complications. Therefore, noninvasive identification of at-risk NASH with an accurate biomarker is a critical need for pharmacologic therapy. We aim to explore the performance of several magnetic resonance (MR)-based imaging parameters in diagnosing at-risk NASH | ||
| 520 | |a APPROACH AND RESULTS: This prospective clinical trial (NCT02565446) includes 104 paired MR examinations and liver biopsies performed in patients with suspected or diagnosed NAFLD. Magnetic resonance elastography-assessed liver stiffness (LS), 6-point Dixon-derived proton density fat fraction (PDFF), and single-point saturation-recovery acquisition-calculated T1 relaxation time were explored. Among all predictors, LS showed the significantly highest accuracy in diagnosing at-risk NASH [AUC LS : 0.89 (0.82, 0.95), AUC PDFF : 0.70 (0.58, 0.81), AUC T1 : 0.72 (0.61, 0.82), z -score test z >1.96 for LS vs any of others]. The optimal cutoff value of LS to identify at-risk NASH patients was 3.3 kPa (sensitivity: 79%, specificity: 82%, negative predictive value: 91%), whereas the optimal cutoff value of T1 was 850 ms (sensitivity: 75%, specificity: 63%, and negative predictive value: 87%). PDFF had the highest performance in diagnosing NASH with any fibrosis stage [AUC PDFF : 0.82 (0.72, 0.91), AUC LS : 0.73 (0.63, 0.84), AUC T1 : 0.72 (0.61, 0.83), |z| <1.96 for all] | ||
| 520 | |a CONCLUSION: Magnetic resonance elastography-assessed LS alone outperformed PDFF, and T1 in identifying patients with at-risk NASH for therapeutic trials | ||
| 650 | 4 | |a Clinical Trial | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, N.I.H., Extramural | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Research Support, U.S. Gov't, Non-P.H.S. | |
| 650 | 7 | |a Protons |2 NLM | |
| 700 | 1 | |a Lu, Xin |e verfasserin |4 aut | |
| 700 | 1 | |a Zhu, Zheng |e verfasserin |4 aut | |
| 700 | 1 | |a Kalutkiewicz, Kyle J |e verfasserin |4 aut | |
| 700 | 1 | |a Mounajjed, Taofic |e verfasserin |4 aut | |
| 700 | 1 | |a Therneau, Terry M |e verfasserin |4 aut | |
| 700 | 1 | |a Venkatesh, Sudhakar K |e verfasserin |4 aut | |
| 700 | 1 | |a Sui, Yi |e verfasserin |4 aut | |
| 700 | 1 | |a Glaser, Kevin J |e verfasserin |4 aut | |
| 700 | 1 | |a Hoodeshenas, Safa |e verfasserin |4 aut | |
| 700 | 1 | |a Manduca, Armando |e verfasserin |4 aut | |
| 700 | 1 | |a Shah, Vijay H |e verfasserin |4 aut | |
| 700 | 1 | |a Ehman, Richard L |e verfasserin |4 aut | |
| 700 | 1 | |a Allen, Alina M |e verfasserin |4 aut | |
| 700 | 1 | |a Yin, Meng |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Hepatology (Baltimore, Md.) |d 1983 |g 78(2023), 4 vom: 01. Okt., Seite 1200-1208 |w (DE-627)NLM012603902 |x 1527-3350 |7 nnns |
| 773 | 1 | 8 | |g volume:78 |g year:2023 |g number:4 |g day:01 |g month:10 |g pages:1200-1208 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1097/HEP.0000000000000417 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 78 |j 2023 |e 4 |b 01 |c 10 |h 1200-1208 | ||